ADICET BIO INC (ACET)
US0070021086 - Common Stock
We assign a fundamental rating of 3 out of 10 to ACET. ACET was compared to 574 industry peers in the Biotechnology industry. ACET has a great financial health rating, but its profitability evaluates not so good. ACET is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ACET had negative earnings in the past year.
In the past year ACET has reported a negative cash flow from operations.
In the past 5 years ACET always reported negative net income.
ACET had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ACET has a Return On Assets (-51.07%) which is in line with its industry peers.
With a decent Return On Equity value of -58.40%, ACET is doing good in the industry, outperforming 61.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.07% | ||
| ROE | -58.4% | ||
| ROIC | N/A |
ROA(3y)-36.07%
ROA(5y)-46.69%
ROE(3y)-42.72%
ROE(5y)-63.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ACET so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ACET does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACET has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ACET has been increased compared to 5 years ago.
There is no outstanding debt for ACET. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACET has an Altman-Z score of -0.81. This is a bad value and indicates that ACET is not financially healthy and even has some risk of bankruptcy.
ACET's Altman-Z score of -0.81 is in line compared to the rest of the industry. ACET outperforms 57.75% of its industry peers.
ACET has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.81 |
ROIC/WACCN/A
WACC10.31%
2.3 Liquidity
A Current Ratio of 12.75 indicates that ACET has no problem at all paying its short term obligations.
ACET has a better Current ratio (12.75) than 85.39% of its industry peers.
ACET has a Quick Ratio of 12.75. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 12.75, ACET belongs to the best of the industry, outperforming 85.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.75 | ||
| Quick Ratio | 12.75 |
3. Growth
3.1 Past
ACET shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.99%.
ACET shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)6.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 11.14% on average over the next years. This is quite good.
ACET is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 157.16% yearly.
EPS Next Y57.93%
EPS Next 2Y23.76%
EPS Next 3Y17.18%
EPS Next 5Y11.14%
Revenue Next Year-100%
Revenue Next 2Y123.62%
Revenue Next 3Y278.31%
Revenue Next 5Y157.16%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ACET. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACET. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ACET's earnings are expected to grow with 17.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.76%
EPS Next 3Y17.18%
5. Dividend
5.1 Amount
No dividends for ACET!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADICET BIO INC
NASDAQ:ACET (9/6/2024, 8:00:00 PM)
After market: 1.56 +0.08 (+5.41%)1.48
+0.04 (+2.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap121.61M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.07% | ||
| ROE | -58.4% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 12.75 | ||
| Quick Ratio | 12.75 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)6.99%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y57.93%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y